Duke researchers hope to learn which forever chemicals are more toxic, and for whom — using tiny worms.

Watch Dean Klotman’s interview with Catherine Liao, Vice President of Duke Health Government Relations. In their conversation, they explore the team's strategic approach to fostering strong relationships with local, state, and national governmental entities, crucial for advancing Duke Health's missions.

A Duke University School of Medicine team reimagines a sci-fi classic as real-world biotech that can speed up biological research.

Gayathri Devi, PhD, MS, professor of surgery and program leader of the Duke Consortium for Inflammatory Breast Cancer, was honored by the Association for Clinical and Translational Science for her work with Rare 2 Care, a global partnership to develop innovative diseases models, therapeutic strategies, and community-engaged research.

New strategy could change how we design drugs—especially the large and polar ones that were once too big to work.

An epic collaboration between neuroscientists at Duke and six other institutions has yielded an AI tool that paves the way for new approaches to treating neurological disorders.

Researchers propose a "treatable fetal findings list" that identifies genetic conditions that can be detected with prenatal testing and treated in utero or in the first week of life.

The event, organized by the Department of Population Health Sciences, spanned topics including including data science and AI, mental health, education, and local and global health challenges.

Sabrina Lewandowski was diagnosed with a usually fatal form of glioblastoma that many centers would have considered untreatable. But the research-intensive team at Duke took a different approach — and 23 years later, she's living her life and raising her 13-year-old daughter.

An unprecedented federal program to support troops' medical needs during World War II led to the emergence of the modern U.S. biomedical system